Simulations Plus, Inc. (NASDAQ:SLP – Free Report) – Analysts at William Blair upped their Q3 2025 EPS estimates for shares of Simulations Plus in a research note issued to investors on Wednesday, January 8th. William Blair analyst M. Smock now anticipates that the technology company will post earnings per share of $0.34 for the quarter, up from their prior forecast of $0.32. William Blair has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.10 per share. William Blair also issued estimates for Simulations Plus’ Q3 2026 earnings at $0.44 EPS.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The business had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year.
Get Our Latest Stock Report on Simulations Plus
Simulations Plus Stock Performance
Shares of SLP stock opened at $28.21 on Thursday. The company has a market capitalization of $566.60 million, a price-to-earnings ratio of 57.57 and a beta of 0.80. Simulations Plus has a one year low of $24.00 and a one year high of $51.22. The company’s 50-day moving average is $29.79 and its 200 day moving average is $34.00.
Insider Transactions at Simulations Plus
In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $27.66, for a total transaction of $553,200.00. Following the completion of the transaction, the director now directly owns 3,462,584 shares in the company, valued at approximately $95,775,073.44. The trade was a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 19.40% of the company’s stock.
Institutional Trading of Simulations Plus
Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC boosted its stake in Simulations Plus by 390.6% in the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock worth $911,000 after purchasing an additional 22,669 shares during the period. Geode Capital Management LLC boosted its position in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after acquiring an additional 18,924 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in Simulations Plus during the second quarter valued at $811,000. State Street Corp increased its holdings in Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after acquiring an additional 28,953 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Simulations Plus by 402.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock worth $1,279,000 after purchasing an additional 32,002 shares in the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Read More
- Five stocks we like better than Simulations Plus
- What Does a Stock Split Mean?
- Why AMD Stock Might Already Be This Year’s Best Buy
- How to Invest in the Best Canadian Stocks
- 3 Promising Penny Stocks to Watch for Long-Term Gains in 2025
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- The 3 Kings of Buybacks in 2024: Can They Do It Again?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.